Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-03 18:36:38时区推断·⟳ 抓取 08-03 18:37:24·⚡ 决策 08-04 08:18:08 +13h40m·84.6 天前
Supernus与Indivior达成全股票合并并拟向Indivior股东派发10亿美元特别股息
交易为合并对等方案：Indivior股东获合并后约56.5%股权并在交割前获10亿美元特别现金股息，Supernus股东按每股1.5401股Indivior换股。
📄 原文Investing.com↗ 原文
Supernus and Indivior agree to merge in all-stock deal
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks ROCKVILLE, Md. and RICHMOND, Va. - Supernus Pha…
不做 Supernus Pharmaceuticals（SUPN.US）
同一合并与10亿美元特别股息催化已在2026-08-03 11:51 UTC由Reuters处理，当前Investing稿为重复转述，不做。
不做 Indivior Pharmaceuticals（INDV.US）
同一合并与10亿美元特别股息催化已在2026-08-03 11:51 UTC由Reuters处理，当前Investing稿为重复转述，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
消息传播链
- Investing转述公司新闻稿，披露全股票合并、10亿美元特别股息、22亿美元收入和8.88亿美元调整后EBITDA口径。市场反应:截至2026-08-04 00:14 UTC，SUPN.US报价较前收+3.07%，INDV.US较前收-6.60%。
- 2026-08-03 11:51 UTC其它search_processed_events非一手已处理消息库已有Reuters同一催化：Supernus与Indivior达成全股票合并并计划10亿美元特别股息。市场反应:命中去重，当前不再输出交易。
关键理由
- 交易为合并对等方案：Indivior股东获合并后约56.5%股权并在交割前获10亿美元特别现金股息，Supernus股东按每股1.5401股Indivior换股。
- 合并公司预计年化收入22亿美元、调整后EBITDA 8.88亿美元并有1.25亿美元年化成本协同，但交易需股东和监管批准且预计到2026年四季度才关闭。
- 已处理消息库在2026-08-03 11:51 UTC已有Reuters同一催化决策，本条为Investing转述，不应重复推卡。
主要风险
- 同一催化已被系统处理，当前输出仅作去重记录。
- 交易结构复杂且仍有股东、监管和交割审批，不适合在重复转述上新开仓。
反向证据
- 做多前查反向 · 来源 search_processed_events · 日期 2026-08-03 · 影响 invalidates
命中2026-08-03 11:51 UTC Reuters同一合并与10亿美元特别股息催化，按去重纪律不再交易。
检索:search_processed_events(hours=72, limit=200, tickers=SUPN.US,INDV.US) - 做多前查反向 · 来源 kb_search · 日期 2026-08-03 · 影响 weakens
内部KB命中SUPN/INDV 8-K和业绩材料，确认该交易已在当天公开文件流中扩散。
检索:Supernus Indivior merger equals $1 billion dividend 2026 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- kb_search · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 2,385 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
ROCKVILLE, Md. and RICHMOND, Va. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) announced today they have entered into a definitive agreement to combine in an all-stock merger of equals transaction, according to a press release statement.
The combined entity will be named Supernus, Inc. and will trade on the Nasdaq Global Market under the ticker symbol SUPN. Jack Khattar, current President and Chief Executive Officer of Supernus Pharmaceuticals, will serve as President and CEO of the combined company. Tony Kingsley, a member of Indivior’s Board of Directors, will serve as Board Chair.
Under the agreement, Supernus Pharmaceuticals stockholders will receive 1.5401 common shares of Indivior Pharmaceuticals for each share they own. Indivior Pharmaceuticals stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing.
To finance the dividend, the companies have secured a debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand.
Upon closing, Indivior Pharmaceuticals stockholders will own approximately 56.5% of the combined company, while Supernus Pharmaceuticals stockholders will own approximately 43.5% on a fully diluted basis.
The combined company is expected to generate pro forma net revenue of $2.2 billion and pro forma adjusted EBITDA of $888 million, including expected annual cost synergies of $125 million. The combined entity will have a commercial portfolio of 11 medicines across psychiatry, neurology and addiction.
The combined company’s Board will have eight directors, including four from each company. Supernus Pharmaceuticals’ headquarters in Rockville, Maryland, will serve as the combined company’s global headquarters.
The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval from both companies, regulatory approvals and customary closing conditions.
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals, while Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ROCKVILLE, Md. and RICHMOND, Va. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) announced today they have entered into a definitive agreement to combine in an all-stock merger of equals transaction, according to a press release statement.
The combined entity will be named Supernus, Inc. and will trade on the Nasdaq Global Market under the ticker symbol SUPN. Jack Khattar, current President and Chief Executive Officer of Supernus Pharmaceuticals, will serve as President and CEO of the combined company. Tony Kingsley, a member of Indivior’s Board of Directors, will serve as Board Chair.
Under the agreement, Supernus Pharmaceuticals stockholders will receive 1.5401 common shares of Indivior Pharmaceuticals for each share they own. Indivior Pharmaceuticals stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing.
To finance the dividend, the companies have secured a debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand.
Upon closing, Indivior Pharmaceuticals stockholders will own approximately 56.5% of the combined company, while Supernus Pharmaceuticals stockholders will own approximately 43.5% on a fully diluted basis.
The combined company is expected to generate pro forma net revenue of $2.2 billion and pro forma adjusted EBITDA of $888 million, including expected annual cost synergies of $125 million. The combined entity will have a commercial portfolio of 11 medicines across psychiatry, neurology and addiction.
The combined company’s Board will have eight directors, including four from each company. Supernus Pharmaceuticals’ headquarters in Rockville, Maryland, will serve as the combined company’s global headquarters.
The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval from both companies, regulatory approvals and customary closing conditions.
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals, while Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。